Abstract: Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. The peptides have the structure: Ac-.beta.-D-NAL-R.sub.2 -D-3PAL-Ser-Arg-R.sub.6 -Leu-Arg-Pro-R.sub.10 wherein R.sub.2 is Cl-D-Phe, F-D-Phe, NO.sub.2 -D-Phe, Br-D-Phe, 3,4Cl.sub.2 -D-Phe or C.alpha.Me-Cl-D-Phe; R.sub.6 is D-3PAL, D-Trp, For-D-Trp, NO.sub.2 -D-Trp, (imBzl)D-His, D-Tyr or .beta.-D-NAL; and R.sub.10 is Gly-NH.sub.2, NHCH.sub.2 CH.sub.3, NHNHCONH.sub.2 or D-Ala-NH.sub.2.

Abstract: The chemical structure of the luteinizing hormone releasing hormone (LHRH) was elucidatd in 1971. Since then, a very large number of international investigators synthesized more than 100 monosubstituted and about 14 disubstituted analogs of LHRH. All of these analogs were synthesized from natural amino acids having the L-configuration. Not one of these approximately 114 analogs showed agonist activity equivalent to that of LHRH. Two of the 114 were about 60% as active, and neither one has had any utility. We have investigated the six individual L-amino acids which occur in positions 5, 7, and 8 of the four naturally occurring LHRH's which exist in porcine/ovine, salmon, and chicken tissue.

Abstract: A peptide with C-terminal proline amide is produced by reacting in aqueous solution a protein substrate having C-terminal prolyl-leucine, prolyl-isoleucine, prolyl-valine, or prolyl-phenylalanine with carboxypeptidase Y in the presence of ammonia. The ammonia is preferably generated by the aqueous reaction of an ammonium salt and an alkali. An example of the peptide product is human calcitonin.

Abstract: Incorporation of a ketomethylene or a hydroxyethylene group in place of the amide linking group between the Pro.sup.9 and Gly.sup.10 residues of LHRH and its analogs improves the oral activity of LHRH or its analogs.

Abstract: Synthetic nonapeptide and decapeptide LHRH antagonist analogues having a halo lower alkyl guanadino-substituted amino acyl residue at position six are disclosed herein.

Abstract: Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads, which can be used for therapeutic treatment. The peptides have the structure:X-R.sub.1 -R.sub.2 -R.sub.3 -Ser-Arg-R.sub.6 -R.sub.7 -Arg-Pro-R.sub.10 wherein X is hydrogen, Acr or Ac; R.sub.1 is .beta.-D-2NAL, dehydroPro or 4Cl-D-Phe; R.sub.2 is Cl-D-Phe, F-D-Phe, NO.sub.2 -D-Phe, Br-D-Phe or C.sup.a Me/Cl-D-Phe; R.sub.3 is D-Trp or .beta.-D-2NAL; R.sub.6 is D-Tyr, .beta.-D-2NAL or D-Arg; R.sub.7 is Leu or NML; and R.sub.10 is Gly-NH.sub.2, NHCH.sub.2 CH.sub.3 or D-Ala-NH.sub.2 ; provided however that R.sub.1 or R.sub.3 or both are .beta.-D-2NAL.

Abstract: GnRH peptide analogs which regulate the secretion of gonadotropins by the pituitary gland and either promote or inhibit the release of steroids by the gonads. Administration of an effective amount of a GnRH antagonist prevents ovulation of female mammalian eggs and/or the release of gonadotropins. Administration of GnRH agonists can be used to regulate fertility in male and female mammals.These and other peptide hormones exhibit improved binding efficiency and biological potency as a result having a residue in a critical, generally central location in the chain which residue contains a mixed alkyl ketone side-chain terminating in an aromatic group. Methods for efficiently synthesizing these peptides from readily available compounds are disclosed.

Abstract: Synthetic nonpeptide and decapeptide LHRH antagonist analogs have a novel guanido-substituted, amidine, tertiary or quaternary amine water-soluble aminoacyl residue at position 6.

Abstract: Novel peptides of the formula: ##STR1## where R.sup.1 through R.sup.8 are various radicals derived from L- and D- amino acids; having LHRH antagonist activity; useful in reducing fertility.Pharmaceutical compositions and methods for use in reducing fertility.

Abstract: Two sets of hormonal peptides are synthesized which are super agonists of the lutenizing hormone releasing hormone (LHRH). Chronic administration results in the inhibition of LHRH which is responsible for stimulating cell growth in the testes. One peptide has the D(dextro)-form of a mono-heterocyclic amino acid in position six (D-3-pyridyl-alanine) while the other peptide has a bi-heterocyclic amino acid in that same position (.beta.-(3-quinolyl)-D-.alpha.-alanine. Both peptides are less metabolically reactive than those in the prior art and yet both peptides are significantly more potent than LHRH itself.

Abstract: Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. The peptides have the structure: X-R.sub.1 -R.sub.2 -R.sub.3 -Ser-Tyr-R.sub.6 -R.sub.7 -Arg-Pro-R.sub.10 wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R.sub.1 is dehydro-Pro or .beta.-D-NAL; R.sub.2 is Cl-D-Phe, F-D-Phe, NO.sub.2 -D-Phe, C.sup..alpha. Me-4-Cl-D-Phe, Cl.sub.2 -D-Phe or Br-D-Phe; R.sub.3 is D-Trp, substituted D-Trp, .beta.-D-NAL, or D-PAL; R.sub.6 is a D-isomer of a lipophilic amino acid or is 4-NH.sub.2 -D-Phe, D-Lys, D-Orn, D-Har, D-His, 4-gua-D-Phe, D-PAL or D-Arg; R.sub.7 is Nle, Phe, Met, Tyr, Nva, Trp, Cys, PAL or 4F-D-Phe; and R.sub.10 is Gly-NH.sub.2 or D-Ala-NH.sub.2 ; provided however that when R.sub.1 is .beta.-D-NAL, then R.sub.6 is 4-NH.sub.2 -D-Phe, D-Lys, D-Orn, D-Har, D-His, 4-gua-D-Phe, D-PAL or D-Arg.

Abstract: A decapeptide of the formula: Ac-A.sup.1 -A.sup.2 -D-Trp-Ser-Tyr-A.sup.3 -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -NH.sub.2 wherein each A.sup.1 and A.sup.2, independently, is D-Trp, D-.beta.-Nal, or D-p-X-Phe, wherein X is a halogen or CH.sub.3 ; A.sup.3 is D-.beta.-Nal, D-Trp, D-Lys, D-Arg, D-homo-Arg, D-diethyl-homo-Arg, or D-p-X-Phe, wherein X is a halogen or CH.sub.3 ; A.sup.4 is Phe, Tyr, pentafluoro-Phe, Trp, .beta.-Nal, or p-X-Phe, wherein X is a halogen or CH.sub.3 ; A.sup.5 is Arg or Lys; A.sup.6 is Pro or hydroxy-Pro; and A.sup.7 is Gly or D-Ala; or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to gonadoliberin derivatives of the general formula (I)Glp--His--Trp--Ser--Tyr--X.sub.1 --X.sub.2 --X.sub.3 --Pro--X.sub.4whereinX.sub.1 is a glycyl group or a D-isomer of any natural or synthetic amino acid group,X.sub.2 represents an L-amino acid group having 1 to 4 carbon atoms in the side chain, L-phenyl-alanyl or L-tryptophyl group,X.sub.3 represents an L-amino acid group having a C.sub.1-4 alkyl or C.sub.2-4 alkanoyl-amide side chain, andX.sub.4 is a glycine amide or a C.sub.1-4 alkyl amide group,with the proviso that if X.sub.1 stands for a group other than glycyl and X.sub.2 is a tryptophyl group then X.sub.3 may not be leucyl, and the addition salts formed with therapeutically useable acids and complexes thereof. Furthermore the invention relates to a process for preparing these compounds.The new gonadoliberin derivatives can be effectively used for the reproduction process of fish, birds and mammals.

Abstract: Two sets of hormonal peptides are synthesized which are super agonists of the luteinizing hormone releasing hormone (LHRH). Chronic administration results in the inhibition of LHRH which is responsible for stimulating cell growth in the testes. One peptide has the D(dextro)-form of a monoheterocyclic amino acid in position six (D-3-pyridyl-alanine) while the other peptide has a bi-heterocyclic amino acid in that same position (.beta.-(3-quinolyl)-D-.alpha.-alanine. Both peptides are less metabolically reactive than those in the prior art and yet both peptides are significantly more potent than LHRH itself.

Abstract: The invention relates to an immunogenic principle containing a specific antigen determinant of a predetermined native antigen. This immunogenic principle is constituted by a conjugate between a hapten bearing said antigenic site and a muramyl-peptide, essentially in the absence of supporting macromolecules, this conjugate having an immunogenic effect not only against itself, but also with respect to the native antigen carrying said antigenic site.

Abstract: A compound having the formula K-His-Trp-Ser-Tyr-M-Q-Arg-Pro-T, wherein K is N-Acetyl-Sarconsine or pGlu; is D-Phe, D-Trp, D-.beta.-Naphthylalanine, or D-4-X-Phe, wherein X is OH, F, Cl, Br, or Me; Q is Leu, Phe, 4-X-Phe, Trp, or .beta.-Naphthylamine (wherein X is OH, F, Cl, Br, or Me), or an N-Me-derivative thereof; and T is Gly-NH.sub.2, NHCH.sub.3, NHCH.sub.2 CH.sub.3, or NHCH.sub.2 CH.sub.2 CH.sub.3 ; provided that, when Q is Leu or N-Me-Leu, K cannot be pGlu; or a pharmaceutically acceptable salt thereof.

Abstract: Therapeutically useful pseudopeptides characterized by the replacement of at least one peptide group, both in a naturally occurring peptide or protein by a thiomethylene group are useful in the treatment of various metabolic malfunctions.

Abstract: The invention relates to novel peptides and peptide derivatives which act as antagonists of natural LH-RH and have the general formula:X-R.sup.1 -R.sup.2 -R.sup.3 -Ser-Tyr-R.sup.4 -R.sup.5 -R.sup.6 -R.sup.7 -R.sup.8 -NH.sub.2whereinX represents hydrogen or a lower acyl(1-6 C) group,R.sup.1 and R.sup.2 represent either the same or different groups selected from D-Bal(2), D-Bal(3), D-Nal(1), D-Nal(2), D-Phe or D-Phe substituted at the phenyl moiety by one or more halogen, alkyl(1-4 C), alkoxy (1-4 C) or nitro groups;R.sup.3 represents D-Trp, D-Bal(2), D-Bal(3), D-Nal(1), D-Nal(2) or D-Pal, with the proviso that at least one of the symbols R.sup.1 and R.sup.3 represents a D-Bal(2) or D-Bal(3) group;R.sup.4 represents D-Arg, D-Lys, D-homo Arg or D-dialkyl (1-4 C)-homo Arg;R.sup.5 represents L-Leu, L-Met or the alkyl(1-4C) or phenylalkyl(7-10C) ether of L-Cys, L-Ser or L-homo Ser;R.sup.6 represents L-Lys or L-Arg;R.sup.7 represents L-Pro or L-thiaprolyl, andR.sup.8 represents D-Ala or Gly.

Abstract: Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. The peptides have the structure:X-R.sub.1 -R.sub.2 -D-Trp-Ser-R.sub.5 -R.sub.6 -Leu-Arg-Pro-R.sub.10wherein X is hydrogen or an acyl group having 7 or less carbon atoms; R.sub.1 is dehydro-Pro, D-pGlu, D-Phe, D-Trp or .beta.-D-NAL; R.sub.2 is Cl-D-Phe, F-D-Phe, C.sup..alpha. Me-4-Cl-D-Phe, NO.sub.2 -D-Phe, Cl.sub.2 -D-Phe or Br-D-Phe; R.sub.5 is Tyr, I-Tyr, CH.sub.3 -Phe, F-Phe or Cl-Phe; R.sub.6 is a D-isomer of a lipophilic amino acid or is 4-NH.sub.2 -D-Phe, 4-gua-D-Phe, D-His, D-Lys, D-Orn, D-Har or D-Arg; and R.sub.10 is Gly-NH.sub.2, D-Ala-NH.sub.2 or NH-Y, with Y being lower alkyl, cycloalkyl, fluoro lower alkyl or ##STR1## where Q is H or lower alkyl. When R.sub.1 is .beta.-D-NAL, R.sub.6 is 4-NH.sub.

Abstract: A synthetic hormone complex comprising means for binding to the surface of a cell and means for altering second messenger mobilization by the cell. One form of the synthetic hormone complex functions as an antagonist with specific binding affinity for a cell receptor, said hormone in combination with a calcium ion channel inhibitor. Another synthetic hormone complex functioning as an Agonist comprising two or more molecules of a hormone having specific binding affinity for a cell receptor wherein a spacer binding the hormones is 10 to 300 angstroms in length. A method of regulating hormones or other regulatory factors comprising contacting a synthetic hormone complex with a cell surface or internal receptor thereby altering the incorporation of second messenger molecules thereby regulating the physiological function of the cell.

Abstract: A conjugate between a nona- or decapeptide of the formula (i) or (ii):Lys-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH.sub.2, (i)orCys-Lys-Trp-Ser-Try-Gly-Leu-Arg-Pro-Gly-NH.sub.2, (ii)or mixtures of peptides (i) and (ii).and a protein is provided which, when used per se or when mixed with a suitable adjuvant, yields a vaccine which acts as an immunogen for LHRH and induces a mammal to produce antibodies which react with LHRH. Immunization against the body's LRHR results in lowering of male and female sex hormones including luteinizing hormone so as to prevent conception. Other uses for materials which lessen the effect of LHRH in the body are known in the art.